Division of Transplantation
The division of transplantation provides kidney, pancreas and liver transplantation, as well as a variety of non-transplant surgical services. The division is a leader in laparoscopic nephrectomy, immunosuppressive drug development, corticosteroid elimination, laparoscopic liver surgery, robotic-assisted surgery, dialysis access research and the development of kidney exchange programs.
The division provides leadership to the Israel Penn Center for Transplant Oncology, the largest and most comprehensive transplant tumor registry in the world. The division has made a permanent commitment to preserve the function of the IPITTR by hiring and supporting faculty whose academic careers support IPITTR-related objectives.
The transplant division has performed more than 800 laparoscopic living donor nephrectomies and performs 100 percent of living-donor nephrectomies laparoscopically. Simultaneous kidney-pancreas, pancreas after kidney and solitary pancreas transplants are performed by division faculty.
The division of transplantation performs over 150 kidney transplants yearly. The division also performs approximately 70 liver transplants per year. The division has excelled in the area of hepatobiliary surgery for benign and malignant tumors of the pancreas, liver and biliary tree, having performed over 1,000 advanced hepatobiliary surgical procedures. The division is a world leader in experience performing laparoscopic liver resections and has hosted several training courses. The transplant division has also developed clinical and research programs in transplant metabolic surgery that has led to the elimination of obesity as a barrier for kidney transplantation.
The transplant division has developed a world-class immunosuppressive drug development program as well as clinical trials in the kidney, islet cell and pancreas transplant programs. Funded studies include several large, multicenter trials with UC as the flagship center.
The transplant division also has recently developed a program in transplant outcomes research. A number of research projects are currently ongoing related to transplant outcomes research, including one such as living donor and deceased donor live transplantation and readmissions following liver transplantation
The transplant division has also developed a dedicated Sensitized Patient Clinic for potential kidney transplant patients who are highly sensitized to HLA antigens. This clinic is one of a very small number of such dedicated clinics in the United States and offers kidney exchange as both clinical and research based desensitization.
The division has pioneered the use of plasma cell targeted therapy for desensitization in highly sensitized transplant recipients, and is currently conducting a second generation trial using combination therapies based on proteasome inhibition. The division also has an active research program in outcomes based research with several ongoing projects.
Madison Cuffy, MD, MBA
Tayyab Diwan, MD
Alin L. Girnita, MD, D-ABHI
Rino Munda, MD
Flavio Paterno, MD
Shimul A. Shah, MD, MHCM
Adele Rike Shields, PharmD
E. Steve Woodle, MD